H.C. Wainwright analyst Swayampakula Ramakanth has maintained their bullish stance on ABSI stock, giving a Buy rating on December 12.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Swayampakula Ramakanth’s rating is based on the potential of AbSci’s ABS-201 program, which targets androgenetic alopecia (AGA) through a prolactin receptor (PRLR) antibody. The mechanism involves blocking prolactin signaling, potentially shifting hair follicles into a prolonged growth phase, as suggested by promising preclinical data. The program’s robust results in ex vivo human scalp studies and rodent models, where ABS-201 outperformed other treatments like minoxidil, have also contributed to the positive outlook.
The analyst highlights the upcoming proof-of-concept (POC) readout in the second half of 2026 as a key milestone, which could provide the first indications of ABS-201’s efficacy in patients by assessing its impact on target area hair count. Additionally, ongoing and planned clinical studies, such as the single-ascending dose and multiple-ascending dose trials, reinforce confidence in the program by providing early safety and pharmacokinetics data, with full efficacy results expected by early 2027. Given the current stock valuation and the anticipated clinical milestones, Ramakanth believes the stock presents a compelling buying opportunity.
According to TipRanks, Ramakanth is a 5-star analyst with an average return of 18.4% and a 43.40% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Corcept Therapeutics, Nanobiotix, and Evaxion Biotech.
In another report released on December 12, Needham also maintained a Buy rating on the stock with a $7.00 price target.